Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AcelRx Pharmaceuticals, Inc. - Common Stock (NQ: ACRX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AcelRx Pharmaceuticals, Inc. - Common Stock

Three Healthcare Penny Stocks to Watch In The New Year
These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of AcelRx Pharmaceuticals, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
From The Rosen Law Firm, P.A.
Via Business Wire
ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: August 9, 2021
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NASDAQ: ACRX Investor Notice: Deadline on August 9, 2021 in Lawsuit Against AcelRx Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 07/27/2021 -- A Deadline is coming up on August 9, 2021 in the lawsuit for certain investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
From Rosen Law Firm
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
From Rosen Law Firm, P.A.
Via Business Wire
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Investor Notice: Lawsuit Alleges Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 06/22/2021 -- An investor, who purchased NASDAQ:ACRX shares, filed a lawsuit over alleged violations of Federal Securities Laws by AcelRx Pharmaceuticals, Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
From Glancy Prongay & Murray LLP
Via Business Wire
ACRX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACRX
From The Rosen Law Firm, P.A.
Via Business Wire
ACELRX PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.